Levetiracetam
Product Images NDC 62332-626

7 FDA label images from Alembic Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 62332-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 2 (Levetiracetam 03)

Figure 2 (Levetiracetam 03)
A bar graph depicting the percentage of patients at three different treatment groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients, ranging from 0% to 45%. Each bar is labeled with the corresponding percentage value.*
FDA Label Image

Figure 3 (Levetiracetam 04)

Figure 3 (Levetiracetam 04)
A bar graph comparing the percentage of patients between two groups: placebo (104 patients) and Levetiracetam 3000 mg/day (180 patients). The Levetiracetam group shows a higher patient percentage at 39.4% compared to 14.4% for the placebo group. The vertical axis is labeled '% of Patients'.*
FDA Label Image

Figure 4 (Levetiracetam 05)

Figure 4 (Levetiracetam 05)
A bar graph comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows approximately 19.6% of patients, while the Levetiracetam group shows a higher percentage of approximately 44.6% of patients. The y-axis represents the percentage of patients from 0% to 45%.*
FDA Label Image

Figure 6 (Levetiracetam 06)

Figure 6 (Levetiracetam 06)
A bar chart comparing the percentage of patients between two groups: Placebo with 84 patients and Levetiracetam with 79 patients. The percentage of patients is displayed on the vertical axis, with the Placebo group showing 45.2% and the Levetiracetam group showing 72.2%, indicating a higher percentage for Levetiracetam treatment.*
FDA Label Image

100 mg/ml (Levetiracetam 100mgperml)

100 mg/ml (Levetiracetam 100mgperml)
Label for Levetiracetam Oral Solution, USP 100 mg/mL by Alembic Pharmaceuticals Inc. The 16 fl oz (473 mL) bottle label includes dosage instructions, storage conditions, manufacturer information (Lannett Company, Inc.), and a barcode. The label states Rx only and advises dispensing a medication guide to patients.*
FDA Label Image

Figure 1 (Levetiracetam Fig1)

Figure 1 (Levetiracetam Fig1)
A vertical bar chart showing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis represents the percentage of patients, and bars indicate a higher percentage in the Levetiracetam groups compared to placebo.*
FDA Label Image

Structure (Levetiracetam Structure)

Structure (Levetiracetam Structure)
Chemical structure of levetiracetam, showing its molecular arrangement including a pyrrolidone ring, an amide side chain, and an ethyl group attached to the central carbon atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.